News

MS Australia congratulates Dr Therese Burke who has been honoured for her significant service to medicine, particularly multiple sclerosis research, and to nursing, by being made a Member of the Order of Australia (AM) in today’s 2023 Australia Day Honours List.

As well as depleting immune cells, new research shows cladribine (Mavenclad) may impede their movement into brain tissue, preventing further damage by multiple sclerosis.

MS Australia CEO Rohan Greenland answers the question, ‘what are the big breakthroughs that lie ahead?’ He details the latest research, treatments and programs that will propel us faster and further along the ‘pathways to cures’.  

Many people living with multiple sclerosis modify their dietary intake after their MS diagnosis, but there is little evidence that dietary modifications influence MS outcomes. A recent Australian study has explored the impact of diet quality specifically on three common MS symptoms; depression, anxiety and fatigue.

The MS Australia Clinical Trials Network is a central point of information for people interested in participating in clinical trials and research studies in MS, or in finding out more details of studies in MS.

MS Plus employee Ben Holgate says he wants to give something back to the charity where he’s worked for the past five years.

MS Australia will be making a submission advocating for the subcutaneous form of Tysabri® to be listed on the PBS, as we welcome affordable access to all treatment options that have been shown in clinical trials to provide safe and effective treatment for MS.

CEO Rohan Greenland reflects on the achievements over the past year and looks ahead to MS Australia’s goals for 2023, where our focus will remain tightly on supercharging MS research, advocacy, education and awareness.

What happens with MS when you stop a disease-modifying therapy, and what is the ideal time window for starting a new one?

Researchers supported by MS Australia have identified proteins that may be involved in multiple sclerosis susceptibility and disease progression.

Irreverent, a new ten-part crime drama television series airing on Netflix, sought early guidance from MS Australia regarding a character who lives with multiple sclerosis.

As a pioneering mechanical engineer, Gwen Gray was a visionary. Her kindness continues to have an impact beyond her years.

Adaptive clinical trials are new forms of clinical trials that are used to answer complex research questions more efficiently than traditional methods. When used in MS, adaptive clinical trials can deliver more effective therapies to people living with multiple sclerosis sooner, thereby protecting brain health.

MS Australia is honoured to announce Nigel Caswell as the recipient of the 2022 John Studdy Award in recognition of his commitment, dedication and service to people living with MS.

MS Australia CEO Rohan Greenland discusses the need for a national minimum neurological data set to ensure the 1.6m Australians living with these conditions can receive the resources and support required.

The European Committee for Treatment and Research in MS, seen as the pinnacle of scientific and medical research into multiple sclerosis, held its annual meeting in Amsterdam last month. This article provides an overview of some of the key highlights of the conference.

A large international study shows that people living with secondary progressive multiple sclerosis experience different progression trajectories.

Bronwyn spent her childhood watching her mother live with advancing MS. Then she was diagnosed with MS when she was just 25. Now, as a mother of two daughters, she looks to MS research to give her hope for a better tomorrow.